- Home
- RUMBW vs FBIOP Comparison
RUMBW vs FBIOP Comparison
Compare RUMBW & FBIOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RUMBW | FBIOP |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | 156 | 101 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RUMBW | FBIOP |
|---|---|---|
| Price | $0.96 | $13.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.5K | ★ 14.9K |
| Earning Date | 03-28-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $85,651,775.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $0.76 | $4.72 |
| 52 Week High | $4.25 | $14.64 |
Technical Indicators
Market Signals| Indicator | RUMBW | FBIOP |
|---|---|---|
| Relative Strength Index (RSI) | 38.38 | 53.34 |
| Support Level | $0.90 | $6.77 |
| Resistance Level | $2.81 | $14.64 |
| Average True Range (ATR) | 0.11 | 0.53 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 36.89 | 55.56 |
Price Performance
Historical ComparisonAbout RUMBW Rumble Inc. Warrant
Rumble Inc is a free-to-use video-sharing and livestreaming platform where users can watch, share, like, comment, and upload their own videos. Users can follow channels to stay in touch with creators and access video on-demand (VOD) and live content streamed by creators. Geographically, it generates a majority of its revenue from the United States.
About FBIOP Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.